BioAtla (BCAB) Accounts Payables (2020 - 2026)
BioAtla (BCAB) posted quarterly Accounts Payables of $19.1 million for Q1 2026, up 23.82% year-over-year from $15.5 million in Q1 2025, and up 17.0% quarter-over-quarter from $16.4 million in Q4 2025.
BioAtla (BCAB) Accounts Payables (2020 - 2026) Analysis & Trends
BioAtla's Accounts Payables history runs 7 years deep, the most recent figure standing at $19.1 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 23.82% year-over-year to $19.1 million; the TTM figure through Mar 2026 stood at $19.1 million (up 23.82% YoY), while the FY2025 annual figure was $16.4 million, up 759.78% from the prior year.
- Accounts Payables for Q1 2026 stood at $19.1 million, up from $16.4 million in the prior quarter.
- The five-year high for Accounts Payables was $32.1 million in Q2 2023, with the low at $1.2 million in Q1 2022.
- The 5-year median for Accounts Payables is $15.8 million (2024), against an average of $14.0 million.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables plunged 88.39% in 2022, then jumped 1960.97% in 2023.
- BioAtla's Accounts Payables stood at $4.2 million in 2022, then slipped by 9.74% to $3.8 million in 2023, then plunged by 50.2% to $1.9 million in 2024, then jumped by 759.78% to $16.4 million in 2025, then grew by 17.0% to $19.1 million in 2026.
- Business Quant data shows BCAB's Accounts Payables at $19.1 million in Q1 2026, $16.4 million in Q4 2025, and $16.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - | 19.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.45 Mn |
| Mar 31, 2026 | 19.13 Mn |
| Dec 31, 2025 | 16.35 Mn |
| Sep 30, 2025 | 16.81 Mn |
| Jun 30, 2025 | 15.80 Mn |
| Mar 31, 2025 | 15.45 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 18.21 Mn |
| Jun 30, 2024 | 15.80 Mn |
| Mar 31, 2024 | 17.75 Mn |
| Dec 31, 2023 | 3.82 Mn |
| Sep 30, 2023 | 6.29 Mn |
| Jun 30, 2023 | 32.08 Mn |
| Mar 31, 2023 | 24.71 Mn |
| Dec 31, 2022 | 4.23 Mn |
| Sep 30, 2022 | 3.70 Mn |
| Jun 30, 2022 | 24.03 Mn |
| Mar 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | 18.42 Mn |
| Sep 30, 2021 | 24.94 Mn |